Mon Feb 24 11:12:22 UTC 2025: ## Glenmark Pharmaceuticals Settles US Lawsuits for $7 Million
**New Delhi, February 24, 2025** – Glenmark Pharmaceuticals announced today it will pay $7 million to settle three lawsuits in the United States related to generic drugs. The settlements resolve claims against the Mumbai-based company concerning generic versions of the cholesterol drugs Zetia and Vytorin.
The lawsuits, filed by Humana, Centene, and Kaiser, alleged anti-competitive practices stemming from a 2010 agreement Glenmark made with other pharmaceutical companies to settle patent infringement litigation. While Glenmark denies all allegations and asserts no admission of liability, the settlement avoids further legal uncertainty.
Four other plaintiffs—Humana Inc, Centene, Kaiser Foundation Health Plan, Inc, and United Healthcare Services, Inc—initially involved in the litigation opted out of a broader 2023 settlement and had their cases remanded. The subsequent settlement specifically addresses these remaining claims.
Following the announcement, Glenmark shares saw a 2.21% increase, closing at ₹1,328.95 on the BSE.
First Piper 